T-CAR cell-directed immunotherapy for the treatment of acute lymphoid leukemia
DOI:
https://doi.org/10.33448/rsd-v9i11.10372Keywords:
ALL; Antigens; Therapy.Abstract
Introduction: Immunotherapy with T-CAR cells has been used as an alternative method of treatment for Acute Lymphoid Leukemia (ALL). ALL is a pathology in which there is an exacerbated increase in immature young cells, since its most affected cell precursors are T cells and, in most cases, B cells. The objective of this article was to explain the technique of immunotherapy with cells T-CAR, as well as its operation. Methodology: This is a bibliographic review with a qualitative approach of an exploratory type, of which searches were carried out in the main national and international electronic databases: Pubmed, Eletronic Library On-line (SCIELO) Virtual health library (Bvs), Cell, Science, Nature and Scholar Google from 2007 to 2018. Results: ALL is a pathology that affects the production of blood cells such as erythrocytes, megakaryocytes and granulocytes, this is due to the high spread of blasts in the bone marrow. This disease has conventional treatment mainly chemotherapy and radiotherapy, as well as stem cell transplantation, however these methods can cause several complications to the patient. Therapy with T-CAR cells targets the destruction of the individual's B cells, through the recognition of specific antigens on these cells (CD19). Conclusion: Treatment with T-CAR cells shows adverse effects of low severity compared to conventional therapies (chemotherapy and radiotherapy). Therefore, this immunotherapy may favor, in the future, a high number of patients fighting not only ALL, but also several other diseases.
References
Cavalcante, M. S., Rosa, I. S. S., & Torres, F. (2017). Leucemia linfoide aguda e seus principais conceitos. Revista Científica da Faculdade de Educação e Meio Ambiente, 8(2), 151-164.
Chauffaille, M. L. L. F., & Yamamoto, M. (2013). Classificação das leucemias agudas: citologia, citoquímica, imunofenotipagem. Zago MA, Falção RP; Pasquini R. Tratado de Hematologia. São Paulo: Ed. Atheneu, 335-42.
Davila, M. L., & Sadelain, M. (2016). Biology and clinical application of CAR T cells for B cell malignancies. International journal of hematology, 104(1), 6-17.
Elman, I., Silva, M. E. M. P. (2007). Crianças portadoras de leucemia linfoide aguda: análise dos limiares de detecção dos gostos básicos. Revista Brasileira de Cancerologia, 53, (3), 297-303.
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013). CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PloS one, 8(4), e61338.
Falcão, R. P., Voltarelli, J. C., Malmegrim, K. C. R. (2013). Ontogênese e Diferenciação do Sistema Linfóide: Dinâmica dos Linfócitos. Imunidade Humoral e Celular. Tratado de hematologia. São Paulo: Atheneu, Cap. 6
Frey, N. V., & Porter, D. L. (2016). CAR T‐cells merge into the fast lane of cancer care. American journal of hematology, 91(1), 146-150.
Gamberale, R. (2014). CAR T cells: Fundamentos de esta prometedora terapia inmunológica. Hematología, 18, 28-31.
Gokbuget, N. et al. (2012). O resultado da leucemia linfoblástica adulta recidivante depende da resposta à quimioterapia de resgate, fatores prognósticos e desempenho do transplante de células-tronco. Sangue. 120 (10).
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., ... & Milone, M. C. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509-1518.
Hoffbrand, A. V., & Moss, P. A. (2013). Fundamentos em hematologia. In Fundamentos em Hematologia (pp. 454-454).
Inca. Instituto nacional do câncer: Leucemia. (2018).
Jensen, M. C., & Riddell, S. R. (2015). Designing chimeric antigen receptors to effectively and safely target tumors. Current opinion in immunology, 33, 9-15.
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013). Gene-engineered T cells for cancer therapy. Nature Reviews Cancer, 13(8), 525-541.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., ... & Mackall, C. L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188-195.
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., ... & Steinberg, S. M. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet, 385(9967), 517-528.
Licínio, M. A., & Silva, M. C. S. D. (2010). Importância da detecção das mutações no gene FLT3 e no gene NPM1 na leucemia mieloide aguda-Classificação da Organização Mundial de Saúde 2008. Revista Brasileira de Hematologia e Hemoterapia, 32(6), 476-481.
Lukashev, A. N., & Zamyatnin, A. A. (2016). Viral vectors for gene therapy: current state and clinical perspectives. Biochemistry (Moscow), 81(7), 700-708.
Martho, L. J., Degasperi, G. R., & Tarsitano, C. A. B. (2017). Imunoterapia com células t-car: bioengenharia contra a leucemia linfoblástica aguda car-t cells. CuidArte, Enferm, 168-173.
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017-4023.
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123(17), 2625-2635.
Noronha, E. P., Marinho, H. T., Thomaz, E. B. A. F., Silva, C. A., Veras, G. L. R., & Oliveira, R. A. G. (2011). Immunophenotypic characterization of acute leukemia at a public oncology reference center in Maranhão, northeastern Brazil. Sao Paulo Medical Journal, 129(6), 392-401.
Rocha, B. C. (2012). Leucemia linfóide aguda: relato de um caso e revisão de literatura.
Spector, N. (2013). Quimioterapia e radioterapia: recaída, remissão e doença residual mínima. In: Zago MA, Falcão RP, Pasquini R. Tratado de hematologia. São Paulo: Atheneu.
Wei, G., Ding, L., Wang, J., Hu, Y., & Huang, H. (2017). Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. Experimental Hematology & Oncology, 6(1), 1-7.
Wood, W. A., & Lee, S. J. (2011). Malignant hematologic diseases in adolescents and young adults. Blood, The Journal of the American Society of Hematology, 117(22), 5803-5815.
Zerbini, M. C. N., Soares, F. A., Velloso, E. D. R. P., & Paes, R. P. (2011). World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 2008–major changes from the 3rd edition, 2001. Revista da Associação Médica Brasileira (English Edition), 57(1), 66-73.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Karolayne Silva Souza; Milena Roberta Freire da Silva; Flávia Steffany Leite Miranda; Kaleen Massari Leite; Jaqueline dos Santos Silva; Rute Medeiros de Sousa; Leandro Paes de Brito; Rodrigo Reges dos Santos Silva; Milena Danda Vasconcelos Santos; Felicson Leonardo Oliveira Lima; Graziele dos Santos ; Renata Pereira Lima da Silva; Diego Canuto Bispo da Silva; Filipe Silva Nunes; Maria Betânia Melo de Oliveira; Isabela Cristina Cordeiro Farias
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
